Latest news with #Biopharma
Yahoo
13-05-2025
- Business
- Yahoo
Grifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year
Net revenues reached EUR 1.786B, up 7.4% in constant currency. Like-for-like net revenues increased by 10.0% in constant currency. Adjusted EBITDA increased to EUR 400M, up 14.2% in constant currency and +21.7% on a constant currency, like-for-like basis. Nacho Abia, Chief Executive Officer, commented: 'Building on our record-setting performances in 2023 and 2024, our first quarter clearly demonstrates continued momentum as we focus on executing our strategic plan. Healthy underlying demand in Biopharma and across all parts of our business, coupled with strong operational execution, positions Grifols (GRFS) for consistent growth throughout 2025. While we continue to monitor evolving macroeconomic and policy developments, the long-established Grifols strategy of being local in our largest markets, where we have established self-sufficient, regional plasma ecosystems with vertically integrated operations, helps to better insulate us from broader marketplace challenges.' Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on GRFS: Disclaimer & DisclosureReport an Issue Grifols SA (GRFS) Q1 Earnings Cheat Sheet Grifols clarifies no knowledge of restarted discussion on offer from Brookfield Grifols approves subsidiary to make public delisting purchase offer to Biotest Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Grifols reaffirms guidance for 2025
Grifols (GRFS) said: 'Grifols remains focused on the continued execution of its strategic plan and reaffirms its guidance for FY2025. Due to the impact of the Inflation Reduction Act on its financial results, Grifols expects to share greater detail in 2025 giving investors and analysts further visibility on its actual performance and underlying momentum. As a result, for 2025, Grifols expects to show both reported figures and LFL figures to make them comparable to previous quarters. LFL figures adjust for the impact on Biopharma performance of both the Inflation Reduction Act Medicare Part D Redesign and the Fee-for-Services reclassification in Q4'24.' Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GRFS: Disclaimer & DisclosureReport an Issue Grifols SA (GRFS) Q1 Earnings Cheat Sheet Grifols clarifies no knowledge of restarted discussion on offer from Brookfield Grifols approves subsidiary to make public delisting purchase offer to Biotest Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
Fresenius SE & Co KGaA (FSNUF) Q1 2025 Earnings Call Highlights: Strong EPS Growth and ...
EPS Growth: Double-digit growth, with core EPS up 12% in Q1. Kabi EBIT Margin: Increased to 16.8%. Organic Revenue Growth: 7% for the group. EBIT Growth: 4% at constant currency. Group EBIT Margin: 11.6%. Net Debt to EBITDA: Within the target range of 2.5 to 3.0. Biopharma Organic Growth: 40% driven by Tien's success. Helios EBIT Margin: 9.8% with strong performance in Spain. Free Cash Flow: Increased by nearly 2 billion. Interest Expense Reduction: Expected reduction of approximately 20 million for the year. Full Year Guidance: Reconfirmed with 7% organic top line growth and 4% EBIT growth at constant currency. Release Date: May 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Fresenius SE & Co KGaA (FSNUF) reported a strong start to 2025 with double-digit EPS growth, reflecting effective capital management and portfolio optimization. The company achieved a 12% increase in core EPS in Q1, driven by growth and earnings expansion across its businesses. Kabi's EBIT margin increased to 16.8%, supported by strong performance in biopharma, nutrition, and medtech sectors. Helios delivered strong top-line growth, with Spain achieving a 13.1% EBIT margin and 23% EBIT growth at constant currency. The company successfully reduced its stake in Fresenius Medical Care, using proceeds to enhance returns and lower debt, strengthening its balance sheet. Negative Points The absence of energy relief in Germany affected Helios' EBIT margin, which was down year-on-year. Potential impacts from global trade uncertainties and tariff policies could affect future economic activity. The weakening of the US dollar against the euro could negatively impact reported revenue and EBIT if it persists. The company faces challenges in maintaining momentum amidst a dynamic macroeconomic and geopolitical environment. Kabi's Q2 performance may be impacted by the absence of the high-margin product Keto in China, affecting revenue and EBIT. Q & A Highlights Q: Can you provide an update on the progress of the biopharma business and its margin expectations? A: Michael Sen, CEO, explained that the biopharma business is progressing well and is approaching the structural EBIT margin range of 16-18%. The business is expected to reach this margin in the midterm, typically within 3 to 5 years, with a potential for earlier achievement if everything aligns well. The focus is on launching new molecules and expanding market share. Q: What are the plans for further deleveraging and balance sheet management? A: Sara Hennicken, CFO, stated that while significant progress was made last year, the pace of deleveraging will be slower in 2025. The focus remains on cash generation and improving EBITDA. The company aims to reach a leverage target of 2.5 to 3 times net debt over EBITDA.
